Thinking of joining a study?

Register your interest

Become a volunteer?

NCT07075471 | RECRUITING | Tenosynovial Giant Cell Tumor

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Sponsor:

Deciphera Pharmaceuticals, LLC

Brief Summary:

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Condition or disease

Tenosynovial Giant Cell Tumor

Study Type : OBSERVATIONAL
Estimated Enrollment : 100 participants
Official Title : Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor
Actual Study Start Date : 2025-09-03
Estimated Primary Completion Date : 2027-09
Estimated Study Completion Date : 2027-09

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Diagnosis of TGCT according to medical records
  • 2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
  • 3. Has provided informed consent and medical records release
Exclusion Criteria
  • 1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
  • 2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
  • 3. Participant is active in an interventional clinical trial of vimseltinib
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Location Details

NCT07075471

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, North Carolina

Synexus Clinical Research, US INC

Wilmington, North Carolina, United States, 28401